WebFeb 10, 2024 · Cynthia Collins owns about 43,760 units of Editas Medicine, Inc … WebJan 23, 2024 · In the meantime, Cynthia Collins, a member of the company’s board, will assume the role of interim CEO. Bosley will remain with Editas in an advisory role through the end of the year in order to ensure a smooth transition, the company said. Neither Editas nor Bosley provided a reason in the announcement for her decision to leave the company.
Editas Medicine Names Cynthia Collins as Interim CEO
WebDec 10, 2024 · CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. WebCYNTHIA COLLINS Editas Medicine he gene edit- ing field reached a mile- stone in March 2024 when for the first time a medicine derived from CRISPR (clustered regularly interspaced short palindromic repeats) genome editing was administered inside a … ikea billy planer download
Cynthia Collins
WebThe chart on this page features a breakdown of the total annual pay for Cynthia Collins … WebCB Rank (Person) 999,792. Primary Job Title Lead Director. Primary Organization. Panavance Therapeutics. Location Cambridge, Massachusetts, United States. Regions Greater Boston Area, East Coast, New England. Gender Female. LinkedIn View on LinkedIn. Cynthia Collins is the Lead Director at Panavance Therapeutics Inc.. WebCynthia Collins served as Chief Executive Officer of Editas Medicine, Inc. … is there ecoli in urine